24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
Spotlight
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
ADHD
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
07:29
MSC denies interest in acquiring ZIM
21:50
Full list of Israeli startup M&As in 2025
21:48
Zendesk acquires AI search startup Unleash for tens of millions
21:03
As Intel stumbles, Nvidia emerges as Israel’s anchor tech employer
More stories
Buzz
Most popular
Daily
Weekly
1
Huang declares Israel Nvidia’s “second home” with record-breaking campus investment
2
Dell acquires AI data-infrastructure startup Dataloop in $120 million all-cash deal
3
Vega raises $120 million Series B as two-year-old cyber startup hits $700 million valuation
4
Cyera raises $400 million at $9 billion valuation in Blackstone-led round
5
Zendesk acquires AI search startup Unleash for tens of millions
More news
ADHD
4 stories about ADHD
“There are so few female founders; this has to be put in the past”
21.08.24
|
Ariela Karmel
Eve Mamane, Co-Founder and CRO of mental health startup Agave Health, spoke to CTech about founding her first venture, the need to normalize female founders, and why the tech industry must eliminate outdated limitations on women in leadership roles
Israeli app launches in the U.S. and Israel, helping parents of ADHD children
15.01.24
|
James Spiro
Pery uses clinical data and LLMs to provide advice and analysis for parents managing children diagnosed with attention deficit hyperactivity disorder
“There is a $5 billion opportunity in the ADHD market”
30.01.23
|
CTech
MindTension has raised a total of $2 million for its tool helping diagnose and treat optimization of ADHD and related mental health comorbidities
Teva Reaches Confidential Patent Settlement with Neos
27.12.18
|
CTech
The agreement will enable Teva to manufacture and sell a generic version of Neos’ ADHD drug Cotempla as of 2026